Searched for
PHARMING
AP EAMCET 2026 Results Link: Check when website link will get active, how to download scorecard, documents required for counsellingAP EAMCET 2026 Results date, time, link: AP EAMCET 2026 results are announced today, June 1, at 11 AM by APSCHE for both Engineering and Ag...- FirstCry, Slice’s FY26 numbers; Nilekani’s Fundamentum eyes deeptech pushFirstCry parent cut its losses in the March quarter on tightened costs. This and more in today's ETtech Top 5.
- Mother's Day Special: How AI, apps are empowering women to manage finances, improve health, build careerWomen are learning to keep pace with the ubiquitous apps and AI, shrugging off dependence on their kids for financial transactions, online ...
- Drugs at your door: Signs of a disruption taking shape in IndiaIndia Pharmacy Retail Quick Commerce: India's medicine delivery is seeing a change. Quick-commerce apps are making it easier to buy medicin...
- Pharmacy startup Plazza in talks to raise $12-15 million from Accel, Nexus, ElevationPlazza, a quick medicine delivery startup, is in talks to secure $12-15 million in funding. This new capital will help Plazza expand its ph...
- PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...
- CCI clears Ranjan Pai’s investment in PharmEasyRanjan Pai invests in PharmEasy's funding with 360 One. API Holdings board seats acquired. Rights issue resolves debt. Monthly burn reducti...
- PharmEasy’s FY23 operating revenue up 16% to Rs 6,644 crore; net loss widens 30%PharmEasy’s parent firm API Holdings cut down its advertising and promotional expenses to Rs 235 crore, less than half of what it incurred ...
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- PharmEasy floats rights issue to raise Rs 750 croreThe company's existing investors like Prosus Ventures and Temasek as well as its founders have subscribed to the issue for shares worth abo...
- PharmEasy parent company gets Sebi nod for Rs 6,250-cr public offerAPI Holdings, the parent firm of PharmEasy, has got clearance from markets regulator Securities and Exchange Board of India for the online ...
- PharmEasy parent API Holdings files papers for Rs 6,250 crore IPOAPI Holdings, the parent of online pharmacy PharmEasy, has filed its draft red herring prospectus (DRHP) with market regulator Sebi for a ₹...
- PharmEasy to acquire 66% stake in Thyrocare for over Rs 4,500 crorePharmEasy is acquiring a majority stake in diagnostics chain Thyrocare Technologies, in what the online pharmacy claimed was the first ever...
- PharmEasy completes acquisition of MedlifeThe company has now become the largest healthcare delivery platform across the country, catering to more than two million families every si...
- Prosus in talks to put $200 million into PharmEasyProsus is expected to get a double-digit stake in PharmEasy's parent. Private equity major TPG Capital is also picking up about 7% stake in...
- PharmEasy in investment talks with Naspers, TPGOnline pharmacies such as PharmEasy and 1mg have registered growth outside their core metropolitan markets by rapidly expanding into tier-2...
- PharmEasy gets a Rs 196-crore booster shot in Series-C round"We will be primarily deploying the money in technology. It is about scaling and using tech to scale, " said Dharmil Sheth, cofounder of Ph...
- Dr Reddy's, TR-Pharm announce collaboration for 3 biosimilarsPharma major Dr Reddy's Laboratories Ltd has entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving three bi...
- Dr Reddy's inks pact with Russian firm R-PharmCommenting on the pact, R-Pharm Chairman Alexey Repik said, "This agreement helps address unmet medical needs in important therapeutic area...
- Panacea to buy 19.9% in PharmAthene for $13.1 mnVaccine maker Panacea Biotec has agreed to buy 19.9% in US-based PharmAthene for $13.1 mn.
Load More
